Holding in Company
Sisäpiiritieto: BEXMAB faasi II -tutkimus saavutti ensisijaisen tavoitteensa hoitoresistentin korkean riskin myelodysplastisen syndrooman ho...
Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS)
Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement to repay its secured loan to IPF and strengthen i...
New analysis and biomarker data strengthens understanding of bexmarilimab’s potential
Board Changes
Results of the Annual General Meeting, Change of Directors, Decision of the Board meeting after the AGM
Shareholders’ Nomination Board updates its recommendation on the number of Board members to be elected and the persons proposed to be electe...
Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS
NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING
Inside Information: Faron Receives Positive EMA Opinion on Orphan Drug Designation for Bexmarilimab for the treatment of myelodysplastic syn...
Faron Pharmaceuticals Ltd’s Annual Report 2024 published
Faron’s Financial Statement Release 1 January to 31 December 2024
Faron Pharmaceuticals will publish its Financial Statement Release 2024 and Annual Report 2024 on Thursday 27 February 2025
Holding(s) in Company
Change of Broker
Inside Information: Announcement of the Results of the Significantly Oversubscribed Placing, the Issue Price and registration of Placing Sha...
Inside Information: Proposed Issue and Placing of preliminarily approx.
Faron Announces Final Patient Identified for the BEXMAB Phase II Study in Myelodysplastic Syndrome
Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024
Faron Confirms Plans for the Coming Months Under New Leadership
Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML
Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab
Faron’s Financial Statement Release January 1 to December 31, 2023
Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
Faron Pharmaceuticals to Present at the 42nd Annual J.
Inside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) A...
Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine
Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register
Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients
Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Ne...
Faron Pharmaceuticals Announces Board Changes
Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting
Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Faron Reports Half-Year Financial Results, January 1 – June 30, 2023
Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia
Faron Pharmaceuticals Notice of Half-Year Financial Results
Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML ...
Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update
